Over the last half year, CeGaT lowered turnaround times and prices for its assays, and its lab recently passed CAP inspection.
Ranomics is building a business around providing functional data on variants of unknown significance, starting with BRCA1 mutations.
Myriad reported revenues of $193.3 million, beating analysts' consensus estimates.
The researchers looked at the first 10,030 consecutive patients referred to GeneDx for germline hereditary cancer panel testing by next-generation sequencing.
The company billed more than 5,100 reports during the third quarter, a 360 percent increase compared to the year-ago period, and accessioned more than 5,400 samples.
The company beat consensus Wall Street estimates for the quarter, reporting revenues of $183.5 million.
If it is able to implement its strategic goals, Myriad projected, it could have $1.5 billion in annual revenues by fiscal year 2020.
Fiscal fourth quarter revenues were $189.9 million, while fiscal year revenues totaled $723.1 million.
So far, results from the MSK-IMPACT test have been reported for more than 4,500 patients.
Data presented at the meeting helped better define the potential benefits and risks of broad panel-based tests for hereditary cancer genes.
The former commissioner of the FDA has returned to the venture capital firm New Enterprise Associates as a special partner on the healthcare investment team.
Astronauts have edited yeast genes on the International Space Station in an experiment designed to show how cells repair themselves in space.
Emory University has found that two of its researchers failed to divulge they had received funds from China, according to the Atlanta Journal-Constitution.
In Science this week: influence of the nuclear genome on human mitochondrial DNA, and more.